Robert Zeiser | Ash 2018 | Novel Therapeutic Strategies For The Treatment Of Steroid-Refractory Gvhd

Robert Zeiser | ASH 2018 | Novel therapeutic strategies for the treatment of steroid-refractory GvHD

Prof. Robert Zeiser | EBMT 2018 | The role of myeloid recipient-derived cells during GvHD

Robert Zeiser | EBMT 2019 | Insights into GvHD pathophysiology and strategies to enhance GVL effects

Prof. H. Joachim Deeg | EBMT 2018 | Treatment of steroid-refractory GvHD with alpha-1-antitrypsin

Ruxolitinib Appears Effective as Treatment of Steroid-Refractory GVHD

Targeted Oncology

REACH3 study: Should ruxolitinib become SoC for steroid-dependent or refractory chronic GvHD?

REACH2: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?

What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?

GVHD Robert Zeiser, MD/ Germany [Session I}

New Dawn for Conference and Medical Conferences

Initial, Steroid-Refractory, and Novel Treatment Options for GVHD

Targeted Oncology

What are the current treatment recommendations for acute GvHD and the promotion of the GvL effect?

Why is it important to assess the organ-specific GvHD responses to treatments?

Managing Steroid-Refractory Acute GVHD

What do you think are the most promising new drugs in the treatment of steroid-refractory cGvHD?

Ruxolitinib: Treatment of Steroid-Refractory Acute GVHD

Steroid-Refractory Chronic GVHD Requires More Treatment Options

Targeted Oncology

Management of acute and chronic GvHD

VJHemOnc – Video Journal of Hematology & HemOnc

Mechanisms of action of ibrutinib, ruxolitinib, and belumosudil, and their role in cGvHD treatment

JAK Inhibitors in Steroid-Refractory GVHD

Targeted Oncology

Pooled allogenic FMT for the treatment of steroid-refractory intestinal acute GvHD

VJHemOnc – Video Journal of Hematology & HemOnc